Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's (PFE.N), opens new tab vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 ; NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) announced today that the ...

EU approves first vaccine against common respiratory virus. London (AFP) – The European Commission has followed the United States in approving the world's first vaccine for the Respiratory ...

The Food and Drug Administration on Wednesday approved the world’s first RSV vaccine: a shot for adults ages 60 and up, made by pharmaceutical giant GSK. The milestone was decades in the making ...

GSK’s RSV vaccine, Arexvy, is approved for use in adults aged 50 years and older in the United States and the EU. This was also the first RSV vaccine to be approved anywhere in the world.

While GSK's vaccine was the first RSV vaccine to be approved by European and U.S. authorities in 2023 for older adults, it has since lagged behind rivals and sales have fallen sharply.

The expanded EU approval, applicable in all 27 countries of the bloc, is for Pfizer's Abrysvo vaccine, which was backed by the European Medicines Agency's panel of experts in March. Sign up here.

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49. NEW YORK, April 01, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. announced today that the European ...